NCT06565689 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 9, 2023

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2026

Conditions

Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Interventions

DRUG

YK012

YK012 is a bispecific antibody targeting CD19 on B cells and CD3 on T cells leading to T cell-mediated cytotoxicity of malignant B cells

Trial Locations (1)

RECRUITING

Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing